Foxo Technologies, Inc., Completes the Acquisition of Revenue Generating Operations From Rennova Health, Inc.

Rhea-AI Summary

FOXO Technologies Inc. (NYSE American: FOXO) has completed the acquisition of two revenue-generating operations from Rennova Health, Inc. (OTC: RNVA). The acquisitions include Myrtle Recovery Centers, Inc., a behavioral health services subsidiary, and Rennova Community Health, Inc. (RCHI), owner of Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center).

Key points:

• Expected to generate over $20M in annual revenue, with potential to reach $50M in 24 months
• RCHI acquisition involved $22M of intercompany Rennova debt and $100
• Myrtle Recovery Centers is a 30-bed behavioral health facility in East Tennessee
• Scott County Community Hospital is a critical access hospital with 2023 revenues of $18.5M and EBITDA over $6M

These acquisitions align with FOXO's strategy to improve healthcare and well-being while significantly boosting revenue.

Positive

• Acquisition of two revenue-generating healthcare operations
• Expected to generate over $20M in annual revenue, with potential to reach $50M in 24 months
• Scott County Community Hospital reported $18.5M revenue and over $6M EBITDA in 2023
• Aligns with FOXO's core strategy of improving healthcare and well-being
• Opens additional opportunities to expand FOXO's technologies in the marketplace

Negative

• Issuance of $22M senior note to Rennova, secured by all assets of RCHI
• Potential dilution risk if RCHI requests to exchange the Note for $20M of Series A preferred stock

Financial Analyst

The acquisition of Rennova Health's operations marks a significant strategic move for FOXO Technologies. With projected annual revenues exceeding $20 million and potential growth to $50 million within 24 months, this deal substantially boosts FOXO's financial outlook. The $22 million debt note structure, convertible to $20 million in preferred stock, provides financial flexibility while minimizing immediate cash outlay. The critical access hospital acquisition is particularly noteworthy, given its $18.5 million revenue and over $6 million EBITDA in 2023, indicating strong profitability. However, investors should monitor integration costs and potential synergies between FOXO's biotech focus and these healthcare operations. The deal's success will hinge on effective management of these diverse assets and leveraging them to enhance FOXO's core epigenetic technology business.

Healthcare Management Expert

FOXO's acquisition of Rennova's assets represents a strategic diversification into direct healthcare services. The addition of a critical access hospital and a behavioral health facility expands FOXO's footprint in rural healthcare, a sector facing significant challenges and opportunities. The 30-bed Myrtle Recovery Centers facility, focusing on addiction treatment, taps into the growing demand for mental health and substance abuse services. With plans to replicate this model, FOXO could establish a scalable network in underserved areas. The Big South Fork Medical Center, as a critical access hospital, likely benefits from enhanced Medicare reimbursements, contributing to its strong EBITDA. This move positions FOXO to potentially integrate its epigenetic technology into clinical settings, creating a unique value proposition in personalized healthcare delivery. However, managing these diverse healthcare operations will require skilled leadership to ensure quality care and operational efficiency.

Biotech Industry Analyst

FOXO's acquisition strategy marks an intriguing pivot from its core focus on epigenetic technology and AI-driven DNA methylation analysis. While this move into direct healthcare provision might seem tangential, it could provide valuable real-world data and clinical application opportunities for FOXO's biotechnology initiatives. The critical access hospital and behavioral health center could serve as testbeds for implementing FOXO's health and longevity solutions, potentially accelerating the development and validation of their epigenetic biomarkers. However, this diversification also introduces new risks and complexities. FOXO will need to balance resource allocation between its biotech R&D and healthcare operations. The success of this strategy will depend on FOXO's ability to create synergies between its technology platform and these new healthcare assets, potentially revolutionizing personalized medicine in rural settings. Investors should closely monitor how effectively FOXO integrates its epigenetic insights into clinical practice at these newly acquired facilities.

Strategic Acquisitions Expected to Generate Over $20M in Annual Revenue, Positioning FOXO for Accelerated Growth

MINNEAPOLIS, MN, Sept. 17, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced it has completed the acquisition of the second revenue-generating operation from Rennova Health, Inc. (OTC: RNVA) (“Rennova”). 

The Company had previously announced it had entered into two share exchange agreements with Rennova. The first agreement was to acquire the equity in Myrtle Recovery Centers, Inc., Rennova’s behavioral health services subsidiary. Closing of the Myrtle transaction occurred on June 14, 2024.

The second agreement was to acquire the equity in Rennova Community Health, Inc. (RCHI), the owner of Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center), a critical access hospital in Tennessee for $20 million of Convertible Preferred Stock in FOXO. On September 10, 2024, the Company entered into an Amended and Restated Stock Exchange Agreement with Rennova to amend the Stock Exchange Agreement dated June 10, 2024, to change the consideration to be received by Rennova in exchange for all of the equity interests of RCHI for $22,000,000 of intercompany Rennova debt and $100. Under the Amendment, RCHI issued a senior note to Rennova in the principal amount of $22,000,000 (subject to adjustments) which will be secured by all of the assets of RCHI, with the Company and Scott County Community Hospital, Inc., a Tennessee corporation, providing a guaranty on the Note pursuant to a Guaranty Agreement dated September 10, 2024, and with the Company providing a security interest in the “Collateral,” as defined in the Pledge and Security Agreement dated September 10, 2024, with Rennova. The Amendment grants RCHI the right to request the Company to exchange the Note into $20,000,000 of Series A preferred stock in the Company.

“We are pleased to have completed these healthcare-related acquisitions from Rennova,” said Mark White, Interim CEO of FOXO Technologies. “These transactions align with our core strategy of improving healthcare and well-being while significantly boosting our revenue. We expect to generate annual revenues in excess of $20 million from these acquisitions, with the potential to reach over $50 million in the next 24 months. Our relationship with Rennova opens additional opportunities to expand FOXO’s technologies in the marketplace, and we believe this is a turning point for FOXO and its shareholders.”

Myrtle Recovery Centers, Inc. is a 30-bed behavioral health facility in East Tennessee. It provides inpatient services for Detox and Residential Treatment and outpatient services for MAT and OBOT Programs. The facility was opened in August 2023 and is in the final stages of securing in-network contracts with various insurance company payers. We anticipate growing this business to having profitable annual revenues of approximately $3-4M and plan to duplicate the model in different locations. Further information can be found at www.myrtlerecoverycenters.com

Scott County Community Hospital, Inc. (DBA Big South Fork Medical) is a critical access designated (CAH) hospital in East Tennessee. 2023 revenues were approximately $18.5M and EBITDA for the facility was in excess of $6M. Further information can be found at www.bsfmedical.com

FOXO Lab’s Inc. (FLI) is a biotechnology company dedicated to improving human health and longevity through the development of cutting-edge technology and product solutions for various industries. FLI’s epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FLI is committed to leveraging the latest advancements in science and technology to help people live better, longer lives. For more information about FLI, visit www.foxotechnologies.com.

About FOXO Technologies Inc. (“FOXO”)

FOXO owns and operates three subsidiaries.

Foxo Lab’s, Inc. is a biotechnology company dedicated to improving human health and longevity through the development of cutting-edge epigenetic and AI technology and product solutions for various health and wellness market sectors.

Myrtle Recovery Centers, Inc., a 30 bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for detox and residential treatment and outpatient services for MAT and OBOT Programs. 

Rennova Community Health, Inc., owns and operates Scott County Community Hospital, Inc. (DBA Big South Fork Medical), a critical access designated (CAH) hospital in East Tennessee.

For more information about FOXO, visit www.foxotechnologies.com.

Forward-Looking Statements

This press release contains certain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements about the delisting of the Warrants from NYSE American, trading of the Warrants in the over-the-counter market, the continued listing of the Company’s Class A common stock on NYSE American, and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. Any such forward-looking statements are based upon the current beliefs and expectations of the Company’s management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond the Company’s control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the possibility that the Plan will not be accepted by NYSE American, the Company will be unable to satisfy other continued listing requirements of NYSE American for its Class A common stock to maintain the listing of the Class A common stock on NYSE American; the risk of changes in the competitive and highly regulated industries in which FOXO operates; variations in operating performance across competitors or changes in laws and regulations affecting FOXO’s business; the ability to implement FOXO’s business plans, forecasts, and other expectations; the ability to obtain financing; the risk that FOXO has a history of losses and may not achieve or maintain profitability in the future; potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans; the enforceability of FOXO’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others; and the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO operates, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties discussed in FOXO’s most recent reports on Forms 10-K and 10-Q, particularly the “Risk Factors” sections of those reports, and in other documents FOXO has filed, or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

Crescendo Communications, LLC
(212) 671-1020
foxo@crescendo-ir.com

FAQ

What companies did FOXO Technologies acquire from Rennova Health?

FOXO Technologies acquired Myrtle Recovery Centers, Inc., a behavioral health services subsidiary, and Rennova Community Health, Inc. (RCHI), owner of Scott County Community Hospital, Inc. (d/b/a Big South Fork Medical Center).

How much annual revenue is expected from FOXO's recent acquisitions?

The acquisitions are expected to generate over $20 million in annual revenue, with potential to reach over $50 million in the next 24 months.

What was the financial performance of Scott County Community Hospital in 2023?

Scott County Community Hospital reported approximately $18.5 million in revenues and EBITDA in excess of $6 million for 2023.

How does the acquisition align with FOXO Technologies' strategy?

The acquisitions align with FOXO's core strategy of improving healthcare and well-being while significantly boosting revenue and opening opportunities to expand FOXO's technologies in the marketplace.